Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI FE 1 20 versus BREVICON 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI FE 1 20 versus BREVICON 28 DAY.
BLISOVI FE 1/20 vs BREVICON 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol, an estrogen, and desogestrel, a progestin, which inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation and altering cervical mucus and endometrial lining to reduce likelihood of fertilization and implantation.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.
One tablet orally once daily for 21 days, followed by 7 days of placebo (iron-containing) tablets. Each active tablet contains 0.1 mg levonorgestrel and 20 mcg ethinyl estradiol.
One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).
None Documented
None Documented
Ethinyl estradiol: ~12-14 hours; norethindrone: ~7-8 hours; both allow once-daily dosing with steady-state reached within 7-10 days.
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-27 hours; half-life for ethinyl estradiol allows once-daily dosing
Renal: ~50-60% as metabolites; fecal: ~40-50% via biliary elimination; less than 10% unchanged in urine.
Renal: ~40% as metabolites and unchanged drug; fecal/biliary: ~60% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive